The votes are nonbinding, but they amount to a rebuke of the FDA’s own scientists who said the drugs have not been studied enough to know whether they are safe or effective.

Emergency presentation (EP) for cancer diagnosis is common among older US adults and predicts persistently elevated mortality, according to a study published online July 14 in the Journal of the ...

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

In the RAS G12-mutated population, daraxonrasib significantly improved median OS (13.2 vs 6.6 months) and median PFS (7.3 vs 3.5 months) compared with chemotherapy. The Food and Drug Administration ...

Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...

Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...

In a scientific statement, the association states that consuming caffeinated coffee linked to reduced risks for type 2 diabetes, heart disease, stroke, heart failure.

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.

Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.